Combined 18 F-FDG and 18 F-Alfatide II PET May Predict Luminal B (HER2 Negative) Subtype and Nonluminal Subtype of Invasive Breast Cancer

作者：Jiang Wu, Xiaoyi Zhang, Zhi‐Jun Jia, Xiaodie Zhou, Rong-Xin Qi, Hengshan Ji, Jingjing Sun, Chuanjin Sun, Zhaogang Teng, Guangming Lu, Xiaoyuan Chen · 发表于：Molecular Pharmaceutics · 年份：2022 · DOI：10.1021/acs.molpharmaceut.2c00547 · 被引用次数：5 · 研究领域：Medical Imaging Techniques and Applications、Radiomics and Machine Learning in Medical Imaging、Radiopharmaceutical Chemistry and Applications

Noninvasive PET molecular imaging using radiopharmaceuticals is important to classify breast cancer in the clinic. The aim of this study was to investigate the combination of 18 F-FDG and 18 F-Alfatide II for predicting molecular subtypes of invasive breast cancer. Forty-four female patients with clinically suspected breast cancer were recruited and underwent 18 F-FDG and 18 F-Alfatide II PET/CT within a week. Tracer uptake in breast lesions was assessed using the maximum standardized uptake value (SUV max ), mean standardized uptake value (SUV mean ), and SUV max ratio of 18 F-FDG to 18 F-Alfatide II (FAR). Invasive breast cancer lesions were further classified as luminal A subtype, luminal B subtype, human epidermal growth factor receptor-2 (HER2) overexpressing subtype, and triple negative subtype according to the expression of the estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki-67. Among 44 patients, 35 patients were pathologically diagnosed with invasive breast cancer. The SUV max and SUV mean of 18 F-FDG were significantly higher in the ER-negative group than those in the ER-positive group, as well as in the PR-negative group than those in the PR-positive group. However, the SUV max and SUV mean of 18 F-Alfatide II were higher in the ER-positive group and the PR-positive group. By combining 18 F-FDG and 18 F-Alfatide II, the FAR was lower in the ER-positive group and the PR-positive group. The HER2 overexpressing subtype showed the highest SUV max and S...